Paxlovid did not reduce the risk of developing long COVID in vaccinated, nonhospitalized adults, according to new data published in the Journal of Medical Virology.

Effective immediately, FDA has changed the labels on two medications used to bring down LDL cholesterol levels: bempedoic acid (Nexletol) and bempedoic acid/ezetimibe (Nexlizet).

In final guidance that takes effect immediately, FDA restricted manufacturers from using benzene in new and existing prescription drugs as well as nonprescription interventions.

FDA gave final approval to required safety labeling updates for opioids. The updates, first included in an April 2023 drug safety communication, include the addition of language stating the risk of overdose increases with higher doses for all opioid analgesics and that immediate-release opioids should not be used for an extended period of time unless a patient’s pain is so severe that it cannot be controlled otherwise.

CDC alerted health care professionals concerning the important need to get Americans vaccinated against influenza, COVID-19, and respiratory syncytial virus (RSV) during the 2023–2024 cold season.